The Unicancer group of Translational research and development in RADiation oncology (UNITRAD)

The UNITRAD cooperative group promotes and develops an innovative and strategic research programme in the field of radiation oncology. It was created in 2014 and brings together approximately 100 experts from various disciplines, such as radiation oncologists, physicists, dosimetrists and statisticians.

President: David AZRIA, Montpellier Cancer Institute (ICM), Montpellier, France

 

UNITRAD aims to develop strategic guidance in the field of radiotherapy, to set up multidisciplinary collaborative networks in France and internationally, and to stimulate and organise innovative research programmes. The group is open to all researchers interested in the development of knowledge in the various fields of radiation

Strategic priorities

  • Integration of biological and physical phenomena
  • Evaluation of new dose delivery methods using external radiotherapy techniques (e.g. intensity-modulated radiation therapy), stereotactic radiotherapy, brachytherapy, intraoperative radiation therapy, proton therapy, MRI-Linac
  • New combinations of radiotherapy with systemic treatments (e.g. targeted therapies or immunotherapies)
  • Standardisation of radiotherapy practices oncology

Expertise and collaboration

UNITRAD closely interacts with Unicancer tumour groups

  • UCBG
  • GETUG
  • UCGI
  • Sarcoma
  • UCH&N

with the support of 9 clusters of expertise

  • Radiobiology and radio-potentiation
  • Modeling and radiomics
  • Quality assurance
  • Humanities and social sciences 
  • Imaging
  • Brachytherapy
  • Physical and technological development
  • Methodology
  • Paediatrics

 

The UNITRAD group in short

 

 

Contact

Jerôme Lemonnier, Breast and Radiation Oncology Programmes Head

Please email us for more information

 

 

Portfolio of active studies

HYPOG-01

Multicenter, randomized phase III trial comparing hypofractionated versus standard radiotherapy in breast cancer with an indication for regional lymph node irradiation in terms of lymphedema occurrence.

Design: Randomised phase III

Tumor: Breast

Study Coordinator: Dr Sofia Rivera,

Gustave Roussy, Villejuif

Study start date:

September 2016

Participating countries: France;

Cooperation with the Danish Breast Cancer

Cooperative Group

Expected number of patients: 1012

 

STEREO-OS

Extracranial Stereotactic Body Radiation Therapy (SBRT) added to standard treatment versus standard treatment alone in solid tumors patients with between 1 and 3 bone-only metastases. Design: Randomised phase III

Tumor: Breast, prostate, lung

Study Coordinator: Dr Sébastien Thureau,

Centre Henri Becquerel, Rouen

Dr Jean-Christophe Faivre, Institut de

cancérologie de Lorraine, Nancy

Study start date:

December 2016

Participating countries: France

Expected number of patients: 196

 

OLIVER

Oligometastases of the Liver treated with chemotherapy with or without extracranial stereotactic body radiation therapy in patients with colorectal cancer. Design: Randomised phase III

Tumor: Colorectal

Study Coordinator: Dr Stéphanie Servagi-

Vernat, Institut Jean Godinot, Reims

Prof Gilles Crehange, Centre Georges-François

Leclerc, Dijon

Study start date:

September 2017

Participating countries: France

Expected number of patients: 158

 

UNITRAD Flagship programme

A major translational ancillary research programme has been developed in association with the HYPOG-01 clinical trial (see above). Using biological samples from around 1000 patients with early breast cancer, this programme aims to develop a multiparametric model in order to identify predictors of normal versus hypofractionated locoregional radiotherapy-induced toxicity.